Intuitive Surgical
U.S. pioneer of robotic-assisted minimally-invasive surgery — the da Vinci Surgical System is the dominant platform globally for general / urological / gynecological / cardiac / thoracic robotic surgery. Imaging-vault relevance: surgical-procedural use of intra-operative imaging (fluoroscopy, ICG fluorescence, CBCT in some hybrid suites) alongside the da Vinci robot. Also the Ion endoluminal system for robotic bronchoscopy.
Company history
- 1995 — founded.
- 1999 — first da Vinci system in clinical use.
- 2000s–2010s — da Vinci installed base grows substantially; becomes the standard for prostatectomy and many gynecological / general-surgical procedures.
- 2018 — Ion endoluminal system launches for robotic bronchoscopy.
- 2024 — da Vinci 5 next-generation platform.
Product line
Surgical robotics
- da Vinci 5 — current flagship; force feedback, integrated cart-based imaging.
- da Vinci Xi — large installed base; current mainstream.
- da Vinci X — value-tier sibling.
- da Vinci SP — single-port platform for specific procedures.
Bronchoscopy robotics
- Ion — robotic endoluminal bronchoscopy + lung-nodule biopsy; competitor to DePuy Monarch.
Distinctive technology
- Wristed instruments — articulated EndoWrist instruments give surgeons restored degrees of freedom in minimally-invasive surgery.
- Firefly fluorescence imaging — ICG-based intra-operative fluorescence for tissue perfusion and tumor / lymphatic identification.
- Integrated visualization + console — surgeon-console + video tower workflow defines the modern robotic-surgery operating-room.
- Ion robotic bronchoscopy — peripheral lung-nodule biopsy with electromagnetic + image-guided navigation.
Market position
Dominant in robotic-assisted minimally-invasive surgery — da Vinci installed base is far larger than any direct competitor. Newer competitors (Medtronic Hugo, J&J Ottava) are early in commercial deployment. Ion competes with DePuy Monarch in the smaller robotic-bronchoscopy category.
Refurb posture
- Vendor-led service contracts dominate; very limited secondary-market activity.
- Da Vinci system + EndoWrist instruments are subscription-class operating expenses; not a typical capital-refurb purchase.
- Pricing model combines capital + per-case instrument cost + service.